SPIBA-101NCT07927972
Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome
StatusNot Yet Recruiting
PhasePhase 1
SponsorStealth BioTherapeutics Inc.
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 0 → 7 locations
- Secondary endpoints: 9 to 1
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Maximum plasma concentration of elamipretide and its metabolites
Timeframe: 24 hours
Area under the plasma concentration time curve from 0 to 24 hours
Timeframe: 24 hours
Secondary (1)
Safety Assessments: Adverse Events and Serious Adverse Events
Arms and interventions
ElamipretideExperimental
SC injection daily
Drugs: Elamipretide
Sites
7 sites in 1 country